Do analysts prefer BYSI or BOLT?

Bolt Biotherapeutics has a consensus price target of $14.50, indicating a potential upside of 267.09%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than BeyondSpring. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bolt Biotherapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Bolt Biotherapeutics (BOLT) Competitors

$3.95 +0.22 (+5.90%)

Closing price 09/11/2026 03:54 PM Eastern

Extended Trading

$3.86 -0.10 (-2.41%)

As of 09/11/2026 07:30 PM Eastern

Compare

BOLT vs. NXTC, ESLA, TCRX, EVAX, and BYSI

Should you buy Bolt Biotherapeutics stock or one of its competitors? Bolt Biotherapeutics's main competitors and comparable companies include NextCure (NXTC), Estrella Immunopharma (ESLA), TScan Therapeutics (TCRX), Evaxion A/S (EVAX), and BeyondSpring (BYSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Bolt Biotherapeutics compare to NextCure?

Bolt Biotherapeutics (NASDAQ:BOLT) and NextCure (NASDAQ:NXTC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, NextCure had 1 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 3 mentions for NextCure and 2 mentions for Bolt Biotherapeutics. NextCure's average media sentiment score of 0.96 beat Bolt Biotherapeutics' score of 0.43 indicating that NextCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
NextCure	Positive

NextCure has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Bolt Biotherapeutics' return on equity of -126.23% beat NextCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
NextCure	N/A	-154.62%	-100.19%

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 42.7% of NextCure shares are owned by institutional investors. 9.4% of Bolt Biotherapeutics shares are owned by company insiders. Comparatively, 11.9% of NextCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Bolt Biotherapeutics presently has a consensus price target of $14.50, indicating a potential upside of 267.09%. NextCure has a consensus price target of $19.00, indicating a potential upside of 171.43%. Given Bolt Biotherapeutics' higher probable upside, equities research analysts plainly believe Bolt Biotherapeutics is more favorable than NextCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NextCure	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Bolt Biotherapeutics has higher revenue and earnings than NextCure. NextCure is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.44	N/A
NextCure	N/A	N/A	-$55.84M	-$8.70	N/A

Bolt Biotherapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market. Comparatively, NextCure has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Summary

Bolt Biotherapeutics beats NextCure on 7 of the 13 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Estrella Immunopharma?

Bolt Biotherapeutics (NASDAQ:BOLT) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Estrella Immunopharma has lower revenue, but higher earnings than Bolt Biotherapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.44	N/A
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.24	N/A

Bolt Biotherapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

In the previous week, Bolt Biotherapeutics and Bolt Biotherapeutics both had 2 articles in the media. Bolt Biotherapeutics' average media sentiment score of 0.43 equaled Estrella Immunopharma'saverage media sentiment score.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Estrella Immunopharma	Neutral

Estrella Immunopharma has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Estrella Immunopharma's return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Estrella Immunopharma	N/A	N/A	-328.72%

Bolt Biotherapeutics currently has a consensus price target of $14.50, indicating a potential upside of 267.09%. Estrella Immunopharma has a consensus price target of $8.00, indicating a potential upside of 1,112.86%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Bolt Biotherapeutics beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to TScan Therapeutics?

Bolt Biotherapeutics (NASDAQ:BOLT) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 6.3% of TScan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, TScan Therapeutics had 9 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 11 mentions for TScan Therapeutics and 2 mentions for Bolt Biotherapeutics. TScan Therapeutics' average media sentiment score of 0.57 beat Bolt Biotherapeutics' score of 0.43 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
TScan Therapeutics	Positive

Bolt Biotherapeutics has a net margin of -611.47% compared to TScan Therapeutics' net margin of -1,655.35%. TScan Therapeutics' return on equity of -108.72% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
TScan Therapeutics	-1,655.35%	-108.72%	-54.47%

Bolt Biotherapeutics has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, TScan Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Bolt Biotherapeutics has higher earnings, but lower revenue than TScan Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.44	N/A
TScan Therapeutics	$10.32M	2.10	-$129.77M	-$0.91	N/A

Bolt Biotherapeutics currently has a consensus price target of $14.50, suggesting a potential upside of 267.09%. TScan Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 732.29%. Given TScan Therapeutics' higher probable upside, analysts plainly believe TScan Therapeutics is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
TScan Therapeutics	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

TScan Therapeutics beats Bolt Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to Evaxion A/S?

Bolt Biotherapeutics (NASDAQ:BOLT) and Evaxion A/S (NASDAQ:EVAX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Evaxion A/S has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. Evaxion A/S's return on equity of -61.43% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%
Evaxion A/S	N/A	-61.43%	-34.23%

Evaxion A/S has lower revenue, but higher earnings than Bolt Biotherapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.44	N/A
Evaxion A/S	$7.53M	3.47	-$7.71M	-$1.21	N/A

Bolt Biotherapeutics has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market. Comparatively, Evaxion A/S has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

86.7% of Bolt Biotherapeutics shares are held by institutional investors. Comparatively, 11.0% of Evaxion A/S shares are held by institutional investors. 9.4% of Bolt Biotherapeutics shares are held by insiders. Comparatively, 41.6% of Evaxion A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bolt Biotherapeutics currently has a consensus price target of $14.50, suggesting a potential upside of 267.09%. Evaxion A/S has a consensus price target of $11.00, suggesting a potential upside of 251.44%. Given Bolt Biotherapeutics' higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Evaxion A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Evaxion A/S	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Bolt Biotherapeutics and Bolt Biotherapeutics both had 2 articles in the media. Bolt Biotherapeutics' average media sentiment score of 0.43 equaled Evaxion A/S'saverage media sentiment score.

Company	Overall Sentiment
Bolt Biotherapeutics	Neutral
Evaxion A/S	Neutral

Summary

Evaxion A/S beats Bolt Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Bolt Biotherapeutics compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, media sentiment, dividends, profitability and analyst recommendations.

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 86.7% of Bolt Biotherapeutics shares are held by institutional investors. 29.3% of BeyondSpring shares are held by company insiders. Comparatively, 9.4% of Bolt Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

BeyondSpring has higher earnings, but lower revenue than Bolt Biotherapeutics. BeyondSpring is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	17.95	-$1.01M	-$0.12	N/A
Bolt Biotherapeutics	$7.70M	0.99	-$33.38M	-$16.44	N/A

In the previous week, Bolt Biotherapeutics had 1 more articles in the media than BeyondSpring. MarketBeat recorded 2 mentions for Bolt Biotherapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.89 beat Bolt Biotherapeutics' score of 0.43 indicating that BeyondSpring is being referred to more favorably in the media.

Company	Overall Sentiment
BeyondSpring	Very Positive
Bolt Biotherapeutics	Neutral

BeyondSpring has a beta of 0.06, meaning that its stock price is 94% less volatile than the broader market. Comparatively, Bolt Biotherapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

BeyondSpring has a net margin of 0.00% compared to Bolt Biotherapeutics' net margin of -611.47%. BeyondSpring's return on equity of 0.00% beat Bolt Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Bolt Biotherapeutics	-611.47%	-126.23%	-54.70%

Bolt Biotherapeutics has a consensus price target of $14.50, indicating a potential upside of 267.09%. Given Bolt Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Bolt Biotherapeutics is more favorable than BeyondSpring.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bolt Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

BeyondSpring and Bolt Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Bolt Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BOLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BOLT vs. The Competition

Export

Metric	Bolt Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.61M	$3.86B	$7.17B	$12.85B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-0.24	14.18	274.94	25.27
Price / Sales	0.99	1,374.95	633.23	90.48
Price / Cash	N/A	106.50	76.65	51.52
Price / Book	0.29	15.12	10.33	6.20
Net Income	-$33.38M	-$22.86M	$3.50B	$358.50M
7 Day Performance	1.28%	-4.34%	-3.32%	-2.35%
1 Month Performance	14.49%	-0.02%	-0.41%	-2.77%
1 Year Performance	-23.75%	40.64%	19.21%	7.63%

Bolt Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BOLT Bolt Biotherapeutics	2.3409 of 5 stars	$3.95 +5.9%	$14.50 +267.1%	-24.4%	$7.61M	$7.70M	N/A	90	Short Interest Increase High Trading Volume
NXTC NextCure	4.1339 of 5 stars	$8.42 +7.7%	$19.00 +125.7%	+28.7%	$28.25M	N/A	N/A	90	Short Interest Decrease
ESLA Estrella Immunopharma	1.7143 of 5 stars	$0.64 -0.9%	$8.00 +1,149.4%	-36.6%	$28.11M	N/A	N/A	N/A	Analyst Downgrade Short Interest Increase Gap Down
TCRX TScan Therapeutics	3.0325 of 5 stars	$0.34 -11.9%	$2.67 +673.4%	-82.7%	$26.54M	$10.32M	N/A	100	News Coverage Analyst Downgrade Analyst Revision
EVAX Evaxion A/S	1.9392 of 5 stars	$3.17 +1.6%	$11.00 +247.0%	+8.7%	$26.02M	$7.49M	N/A	60	Short Interest Increase Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BOLT) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. NXTC, ESLA, TCRX, EVAX, and BYSI

How does Bolt Biotherapeutics compare to NextCure?

Summary

How does Bolt Biotherapeutics compare to Estrella Immunopharma?

Summary

How does Bolt Biotherapeutics compare to TScan Therapeutics?

Summary

How does Bolt Biotherapeutics compare to Evaxion A/S?

Summary

How does Bolt Biotherapeutics compare to BeyondSpring?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bolt Biotherapeutics (BOLT) Competitors

BOLT vs. NXTC, ESLA, TCRX, EVAX, and BYSI

How does Bolt Biotherapeutics compare to NextCure?

Does the media favor BOLT or NXTC?

Is BOLT or NXTC more profitable?

Do insiders and institutionals believe in BOLT or NXTC?

Do analysts rate BOLT or NXTC?

Which has preferable earnings and valuation, BOLT or NXTC?

Which has more risk and volatility, BOLT or NXTC?

Summary

How does Bolt Biotherapeutics compare to Estrella Immunopharma?

Which has stronger valuation & earnings, BOLT or ESLA?

Which has more risk and volatility, BOLT or ESLA?

Does the media prefer BOLT or ESLA?

Is BOLT or ESLA more profitable?

Do analysts recommend BOLT or ESLA?

Do institutionals & insiders believe in BOLT or ESLA?

Summary

How does Bolt Biotherapeutics compare to TScan Therapeutics?

Do insiders & institutionals have more ownership in BOLT or TCRX?

Does the media favor BOLT or TCRX?

Is BOLT or TCRX more profitable?

Which has more risk & volatility, BOLT or TCRX?

Which has better earnings and valuation, BOLT or TCRX?

Do analysts rate BOLT or TCRX?

Summary

How does Bolt Biotherapeutics compare to Evaxion A/S?

Is BOLT or EVAX more profitable?

Which has higher valuation & earnings, BOLT or EVAX?

Which has more volatility & risk, BOLT or EVAX?

Do institutionals & insiders have more ownership in BOLT or EVAX?

Do analysts prefer BOLT or EVAX?

Does the media favor BOLT or EVAX?

Summary

How does Bolt Biotherapeutics compare to BeyondSpring?

Do institutionals and insiders believe in BYSI or BOLT?

Which has higher earnings and valuation, BYSI or BOLT?

Does the media refer more to BYSI or BOLT?

Which has more volatility and risk, BYSI or BOLT?

Is BYSI or BOLT more profitable?

Do analysts prefer BYSI or BOLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT vs. The Competition

Bolt Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools